Effect of PSK and its Subfractions on Peripheral Blood Lymphocytes Mediated Cytotoxicity against Urinary Bladder Tumor Cells
- 1 November 1992
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 148 (5 Part 1) , 1571-1576
- https://doi.org/10.1016/s0022-5347(17)36972-0
Abstract
Our previous studies have indicated that the protein-bound polysaccharide Kreha (PSK) enhances the cytotoxic activity of peripheral blood lymphocytes (PBL) against the T24 human urinary bladder tumor cell line in patients with bladder tumor. Since PSK consists of a mixture of various kinds of protein-bound polysaccharides, the present study was designed to examine which subfractions of PSK mediated the enhancement of cytotoxicity. When PSK was separated according to size, treatment of PBL with the 50 kilodalton (kd) or less fraction killed T24 cells more efficiently than unfractionated PSK-treated PBL. The higher molecular weight fractions did not enhance killing above the control level. PSK was fractionated on a diethylaminoethyl (DEAE)-cellulose column to obtain a protein rich fraction that absorbed onto the column and a polysaccharide rich fraction that did not. PBL treated with the polysaccharide rich fraction were able to kill T24 cells more effectively than unfractionated PSK-treated PBL. The protein rich fraction had no effect on the killing. Further fractionation of the polysaccharide rich fraction was performed by differential precipitation with ammonium sulfate. PBL treated with the precipitated fraction at 70-80% saturation (PSK Fraction D) enhanced cytotoxicity equal to that of the polysaccharide rich fraction. Treatment of PBL with the other fractions did not augment the cytotoxicity. These enhancement by PSK fractions were observed in healthy donors and also in patients with bladder tumor. An increase of the proliferative response of PBL to PSK Fraction D as well as unfractionated PSK was observed. Treatment of PBL with PSK Fraction D had no effect on the proportion of PBL binding to T24 cells, thus suggesting a post-binding effect. The structure of PSK Fraction D as inferred from the results of methylation analysis was mainly an alpha-glucan. These results demonstrate that PSK mediated enhancement of cytotoxicity and proliferation of PBL may be largely due to an alpha-glucan of less than 50 kd.Keywords
This publication has 25 references indexed in Scilit:
- In vitro immunomodulating effect of protein-bound polysaccharide, PSK on peripheral blood, regional nodes, and spleen lymphocytes in patients with gastric cancerCancer Immunology, Immunotherapy, 1991
- Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancerCancer Immunology, Immunotherapy, 1990
- Combined Therapeutic Effects of Conventional Agents and an Immunomodulator, PSK, on Rat Prostatic AdenocarcinomaJournal of Urology, 1989
- A randomized trial of chemoimmunotherapy of acute nonlymphocytic leukemia in adults using a protein-bound polysaccharide preparationCancer Immunology, Immunotherapy, 1984
- Krestin (PSK)Cancer Treatment Reviews, 1984
- The effect of PS-K, a protein bound polysaccharide, on immune responses against allogeneic antigensInternational Journal of Immunopharmacology, 1983
- Antitumour Polysaccharide derived Chemically from Natural Glucan (Pachyman)Nature, 1970
- Inhibition of Mouse Sarcoma 180 by Polysaccharides from Lentinus edodes (Berk.) Sing.Nature, 1969
- Inhibition of Mouse Sarcoma 180 by a Wheat Hemicellulose B PreparationNature, 1967
- Growth Inhibition of Mouse Ascites Tumour Cells by Powdered Tragacanth (Tragacanthæ Pulvis, B.P.)Nature, 1959